{{Rsnum
|rsid=3733223
|Gene=TNIP2
|Chromosome=4
|position=2743781
|Orientation=minus
|GMAF=0.4876
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=TNIP2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 20.4 | 53.1 | 26.5
| HCB | 32.1 | 48.9 | 19.0
| JPT | 21.2 | 52.2 | 26.5
| YRI | 21.8 | 55.1 | 23.1
| ASW | 19.3 | 54.4 | 26.3
| CHB | 32.1 | 48.9 | 19.0
| CHD | 30.3 | 52.3 | 17.4
| GIH | 26.7 | 50.5 | 22.8
| LWK | 26.4 | 47.3 | 26.4
| MEX | 13.8 | 37.9 | 48.3
| MKK | 23.1 | 39.7 | 37.2
| TSI | 24.5 | 51.0 | 24.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs3733223
|Name_s=
|Gene_s=FAM193A, TNIP2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109522
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3733223
|overall_frequency_n=60
|overall_frequency_d=128
|overall_frequency=0.46875
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=49
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}